NEW YORK, Aug. 31, 2017 -- The Klein Law Firm announces that a securities complaint has been filed on behalf of shareholders of ZTO Express (Cayman), Inc. (NYSE:ZTO) who purchased shares pursuant and/or traceable to the Company’s Stock Offering on or about October 27, 2016.
The complaint alleges that the Registration Statement used to conduct the IPO contained inaccurate statements and omitted material information. In particular, the complaint alleges that ZTO Express failed to disclose that: (1) it was improperly inflating its stated profit margins by keeping certain low-margin segments of its business out of its financial statements; (2) it used a system of “network partners” to handle lower-margin pickup and delivery services, while maintaining ownership of core hub operations; and (3) by keeping the “network partners” businesses off its own books, the Company allegedly was able to exaggerate its profit margins to investors.
If you suffered a loss in ZTO Express you have until October 16, 2017 to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
If you suffered a loss in ZTO Express and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/zto-express-cayman-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 



